Secukinumab Use in Psoriatic Arthritis. 2018

Rakesh Kumar Jagdish, and Shailly, and M K Bhatnagar
Consultant Rheumatologist, Kailash and Max Hospital, Noida; Ex. Senior Resident Rheumatology, AIIMS, Delhi.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D015535 Arthritis, Psoriatic A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor. Psoriasis Arthropathica,Psoriasis, Arthritic,Psoriatic Arthritis,Psoriatic Arthropathy,Arthritic Psoriasis,Arthropathies, Psoriatic,Arthropathy, Psoriatic,Psoriatic Arthropathies
D061067 Antibodies, Monoclonal, Humanized Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab. Antibodies, Humanized,Humanized Antibodies
D018501 Antirheumatic Agents Drugs that are used to treat RHEUMATOID ARTHRITIS. Anti-Rheumatic Agent,Anti-Rheumatic Drug,Antirheumatic Agent,Antirheumatic Disease-Modifying Second-Line Drug,Antirheumatic Drug,DMARD,Disease-Modifying Antirheumatic Drug,Disease-Modifying Antirheumatic Drugs,Anti-Rheumatic Agents,Anti-Rheumatic Agents, Non-Steroidal,Anti-Rheumatic Drugs,Antirheumatic Disease-Modifying Second-Line Drugs,Antirheumatic Drugs,Antirheumatic Drugs, Disease-Modifying,Disease-Modifying, Antirheumatic Second-Line Drugs,Agent, Anti-Rheumatic,Agent, Antirheumatic,Anti Rheumatic Agent,Anti Rheumatic Agents,Anti Rheumatic Agents, Non Steroidal,Anti Rheumatic Drug,Anti Rheumatic Drugs,Antirheumatic Disease Modifying Second Line Drug,Antirheumatic Disease Modifying Second Line Drugs,Antirheumatic Drug, Disease-Modifying,Antirheumatic Drugs, Disease Modifying,Disease Modifying Antirheumatic Drug,Disease Modifying Antirheumatic Drugs,Disease Modifying, Antirheumatic Second Line Drugs,Drug, Anti-Rheumatic,Drug, Antirheumatic,Drug, Disease-Modifying Antirheumatic,Non-Steroidal Anti-Rheumatic Agents

Related Publications

Rakesh Kumar Jagdish, and Shailly, and M K Bhatnagar
March 2017, Prescrire international,
Rakesh Kumar Jagdish, and Shailly, and M K Bhatnagar
March 2021, Drugs,
Rakesh Kumar Jagdish, and Shailly, and M K Bhatnagar
July 2016, Drugs,
Rakesh Kumar Jagdish, and Shailly, and M K Bhatnagar
December 2017, Rheumatology and therapy,
Rakesh Kumar Jagdish, and Shailly, and M K Bhatnagar
November 2023, International journal of rheumatic diseases,
Rakesh Kumar Jagdish, and Shailly, and M K Bhatnagar
September 2015, Nature reviews. Rheumatology,
Rakesh Kumar Jagdish, and Shailly, and M K Bhatnagar
January 2016, Therapeutics and clinical risk management,
Rakesh Kumar Jagdish, and Shailly, and M K Bhatnagar
October 2016, Expert review of clinical immunology,
Rakesh Kumar Jagdish, and Shailly, and M K Bhatnagar
April 2021, Drugs,
Copied contents to your clipboard!